S1078 Oral Contraceptives Significantly Reduce the Risk of GERD, Esophagitis and Barrett’s Esophagus

Introduction: Gastroesophageal reflux disease (GERD) affects over 784 million people worldwide. Hormonal contraceptives have been suggested to influence GERD risk due to their effects on gastric acid secretion and esophageal sphincter function. While combined oral contraceptives (COCs) have been more commonly associated with GERD, limited evidence exists on progestin-only contraceptives (POCs). Of women aged 15-49 years, 65% use contraception, with 1 in 4 utilizing oral contraceptive pills. Given their widespread use, this study aimed to compare the incidence of GERD and related esophageal conditions between COC and POC users. Methods: This retrospective cohort study utilized de-identified data from the TriNetX U.S. Collaborative Network, encompassing records from 67 U.S. healthcare organizations. Women aged 18-50 years with documented use of POCs, COCs, or no hormonal contraception between January and December 2014 were included. Patients with pre-existing esophageal conditions or confounding health issues were excluded. Propensity score matching was used to control for variables such as age, body mass index, alcohol use, smoking, and comorbidities. GERD, esophagitis, Barrett’s esophagus, and esophageal cancer were identified using International Classification of Diseases-10 codes, and outcomes were tracked over a 10-year period. Results: After matching, both POC and COC users had significantly lower odds of GERD, esophagitis, and Barrett’s esophagus compared to the control group. GERD incidence was lowest in POC users (9.76%) versus COC users (11.30%) and controls (12.60%). POC users also had a lower risk of esophagitis than both COC users and controls. Both contraceptive groups had reduced odds of Barrett’s esophagus, with no significant difference between them. Esophageal cancer was rare and showed no significant differences across groups. Conclusion: This study demonstrates that both POCs and COCs are associated with a reduced risk of GERD compared to controls, with POCs showing a stronger protective effect. This contrasts with previous findings suggesting estrogen increases GERD risk. The long-term design and rigorous matching in this study may explain the differing results. The protective effect may be attributed to synthetic progestins enhancing lower esophageal sphincter tone and reducing inflammation. Further clinical trials are needed to confirm these results and explore underlying mechanisms.